염증성 장질환에서 유전적 소인과 더불어 장내 미생물의 조성과 면역 반응이 발병과 임상 경과에 중요한 역할을 하고 있다는 것은 이미 잘 알려져 있는 사실입니다. 따라서 염증성 장질환 환자에 대한 진료를 완성해 가기 위해서는 임상의에게도 유전과 면역, 그리고 마이크로바이옴에 대한 깊은 이해가 반드시 선행되어야 하겠습니다. 하지만 많은 임상의사들은 지금껏 해당 분야에 대한 깊이 있는 지식을 가지기 위해 살펴보아야 했음에도 차마 엄두를 내지 못한 경우가 많았습니다. 유전, 면역, 마이크로바이옴 그리고 마이크로바이옴을 면역 연관 염증질환(immune mediated inflammatory disorders; IMIDs) 치료제로서 적용 가능한지에 대한 내용을 이 한 세션에 모두 담았습니다. 존경받는 전문가들이 제공하는 유익한 지식의 장에 여러분을 초대합니다.

We are delighted to announce the launch of this session in collaboration with WEO, the world-leading group in endoscopic research and education, dedicated to promoting high standards and quality in endoscopy. We will closely discuss the emerging issues and future directions of CRC screening with global leaders in the field.

Therapeutic advances in inflammatory bowel disease (IBD) have increased the proportion of patients with favorable clinical courses compared to the pre-biologics era. However, medical treatment for IBD sometimes exposes patients to the risk of various infections. In addition, despite the recent advances in medical treatment for IBD, there are still difficult cases, such as acute severe ulcerative colitis or Crohn’s disease having intraabdominal abscesses or intestinal strictures. In this session, we will discuss the strategies for managing these challenging situations you may encounter in your practice.

The collaboration between Gastroenterology and Radiology is increasingly vital in determining diagnostic and treatment strategies for digestive disorders. In this section, our goal is to explore enhanced approaches to managing Crohn's disease and rectal cancer by leveraging the synergies between these two departments.

CRC screening plays a pivotal role in identifying precancerous lesions or early-stage cancers before symptoms manifest, significantly enhancing the chances of successful treatment and survival. In this section, we will present the latest research findings on FIT-based screening and provide valuable insights into new screening methods.

Meta-Omics are rapidly expanding our knowledge of the gut microbiota. In this session, we will offer a preview of cutting edge IBD research. In particular, we share the latest research on IBD treatment responses and gut microbiome. It will also be an opportunity to discuss interesting results predicting the future of IBD through more advanced metabolomics analysis.

Colorectal ESD is currently established as a treatment method for lesions where en bloc resection is not possible with EMR and cancerous lesions, and is widely practiced. However, colorectal ESD is technically challenging and associated with the risk of adverse events. Therefore, in this session, we will learn from colorectal ESD masters how to go from a beginner to expert and discuss optimal treatment strategies to overcome difficult cases.

Managing IBD goes beyond merely diagnosing and treating the disease; it requires comprehensive care for overall health care. This session explores the metabolic disorders in IBD patients and their clinical implications, as well as cancer prevention in long-term IBD care.

- Prize: USD 200
- Number of winners: 50 Awardees
- Eligibility

• Pre-registration by March 31 (Sun.), 2024 is required.
• Participants of foreign affiliations who are not presenting authors can be candidates for the travel grants. Specifically, foreign participants who did not submit abstracts OR who are corresponding authors or co-authors are eligible.
• Participants from countries listed on the <DAC List of ODA Recipients by OECD> have priority, however, this qualification is only a priority, not mandatory.

IMKASID 2024 Pre-Registration is ongoing! We implore you to register now to take advantage of pre-registration rates and then join the IMKASID 2024!
Some sessions require pre-registration, so don't miss this opportunity.